Marktanalyse - Breast Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
3149 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Breast Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer — Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.

Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.

Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 19

Breast Cancer Overview 20

Therapeutics Development 21

Breast Cancer - Therapeutics under Development by Companies 23

Breast Cancer - Therapeutics under Investigation by Universities/Institutes 66

Breast Cancer - Pipeline Products Glance 75

Breast Cancer - Products under Development by Companies 79

Breast Cancer - Products under Investigation by Universities/Institutes 145

Breast Cancer - Companies Involved in Therapeutics Development 160

Breast Cancer - Therapeutics Assessment 617

Drug Profiles 713

Breast Cancer - Dormant Projects 2934

Breast Cancer - Discontinued Products 3000

Breast Cancer - Product Development Milestones 3013

Appendix 3027





List of Tables

Number of Products under Development for Breast Cancer, H2 2016 142

Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016 143

Number of Products under Development by Companies, H2 2016 145

Number of Products under Development by Companies, H2 2016 (Contd..1) 146

Number of Products under Development by Companies, H2 2016 (Contd..2) 147

Number of Products under Development by Companies, H2 2016 (Contd..3) 148

Number of Products under Development by Companies, H2 2016 (Contd..4) 149

Number of Products under Development by Companies, H2 2016 (Contd..5) 150

Number of Products under Development by Companies, H2 2016 (Contd..6) 151

Number of Products under Development by Companies, H2 2016 (Contd..7) 152

Number of Products under Development by Companies, H2 2016 (Contd..8) 153

Number of Products under Development by Companies, H2 2016 (Contd..9) 154

Number of Products under Development by Companies, H2 2016 (Contd..10) 155

Number of Products under Development by Companies, H2 2016 (Contd..11) 156

Number of Products under Development by Companies, H2 2016 (Contd..12) 157

Number of Products under Development by Companies, H2 2016 (Contd..13) 158

Number of Products under Development by Companies, H2 2016 (Contd..14) 159

Number of Products under Development by Companies, H2 2016 (Contd..15) 160

Number of Products under Development by Companies, H2 2016 (Contd..16) 161

Number of Products under Development by Companies, H2 2016 (Contd..17) 162

Number of Products under Development by Companies, H2 2016 (Contd..18) 163

Number of Products under Development by Companies, H2 2016 (Contd..19) 164

Number of Products under Development by Companies, H2 2016 (Contd..20) 165

Number of Products under Development by Companies, H2 2016 (Contd..21) 166

Number of Products under Development by Companies, H2 2016 (Contd..22) 167

Number of Products under Development by Companies, H2 2016 (Contd..23) 168

Number of Products under Development by Companies, H2 2016 (Contd..24) 169

Number of Products under Development by Companies, H2 2016 (Contd..25) 170

Number of Products under Development by Companies, H2 2016 (Contd..26) 171

Number of Products under Development by Companies, H2 2016 (Contd..27) 172

Number of Products under Development by Companies, H2 2016 (Contd..28) 173

Number of Products under Development by Companies, H2 2016 (Contd..29) 174

Number of Products under Development by Companies, H2 2016 (Contd..30) 175

Number of Products under Development by Companies, H2 2016 (Contd..31) 176

Number of Products under Development by Companies, H2 2016 (Contd..32) 177

Number of Products under Development by Companies, H2 2016 (Contd..33) 178

Number of Products under Development by Companies, H2 2016 (Contd..34) 179

Number of Products under Development by Companies, H2 2016 (Contd..35) 180

Number of Products under Development by Companies, H2 2016 (Contd..36) 181

Number of Products under Development by Companies, H2 2016 (Contd..37) 182

Number of Products under Development by Companies, H2 2016 (Contd..38) 183

Number of Products under Development by Companies, H2 2016 (Contd..39) 184

Number of Products under Development by Companies, H2 2016 (Contd..40) 185

Number of Products under Development by Companies, H2 2016 (Contd..41) 186

Number of Products under Investigation by Universities/Institutes, H2 2016 187

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 188

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 189

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 190

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 191

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 192

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 193

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 194

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 195

Comparative Analysis by Late Stage Development, H2 2016 196

Comparative Analysis by Clinical Stage Development, H2 2016 197

Comparative Analysis by Early Stage Development, H2 2016 198

Comparative Analysis by Unknown Stage Development, H2 2016 199

Products under Development by Companies, H2 2016 200

Products under Development by Companies, H2 2016 (Contd..1) 201

Products under Development by Companies, H2 2016 (Contd..2) 202

Products under Development by Companies, H2 2016 (Contd..3) 203

Products under Development by Companies, H2 2016 (Contd..4) 204

Products under Development by Companies, H2 2016 (Contd..5) 205

Products under Development by Companies, H2 2016 (Contd..6) 206

Products under Development by Companies, H2 2016 (Contd..7) 207

Products under Development by Companies, H2 2016 (Contd..8) 208

Products under Development by Companies, H2 2016 (Contd..9) 209

Products under Development by Companies, H2 2016 (Contd..10) 210

Products under Development by Companies, H2 2016 (Contd..11) 211

Products under Development by Companies, H2 2016 (Contd..12) 212

Products under Development by Companies, H2 2016 (Contd..13) 213

Products under Development by Companies, H2 2016 (Contd..14) 214

Products under Development by Companies, H2 2016 (Contd..15) 215

Products under Development by Companies, H2 2016 (Contd..16) 216

Products under Development by Companies, H2 2016 (Contd..17) 217

Products under Development by Companies, H2 2016 (Contd..18) 218

Products under Development by Companies, H2 2016 (Contd..19) 219

Products under Development by Companies, H2 2016 (Contd..20) 220

Products under Development by Companies, H2 2016 (Contd..21) 221

Products under Development by Companies, H2 2016 (Contd..22) 222

Products under Development by Companies, H2 2016 (Contd..23) 223

Products under Development by Companies, H2 2016 (Contd..24) 224

Products under Development by Companies, H2 2016 (Contd..25) 225

Products under Development by Companies, H2 2016 (Contd..26) 226

Products under Development by Companies, H2 2016 (Contd..27) 227

Products under Development by Companies, H2 2016 (Contd..28) 228

Products under Development by Companies, H2 2016 (Contd..29) 229

Products under Development by Companies, H2 2016 (Contd..30) 230

Products under Development by Companies, H2 2016 (Contd..31) 231

Products under Development by Companies, H2 2016 (Contd..32) 232

Products under Development by Companies, H2 2016 (Contd..33) 233

Products under Development by Companies, H2 2016 (Contd..34) 234

Products under Development by Companies, H2 2016 (Contd..35) 235

Products under Development by Companies, H2 2016 (Contd..36) 236

Products under Development by Companies, H2 2016 (Contd..37) 237

Products under Development by Companies, H2 2016 (Contd..38) 238

Products under Development by Companies, H2 2016 (Contd..39) 239

Products under Development by Companies, H2 2016 (Contd..40) 240

Products under Development by Companies, H2 2016 (Contd..41) 241

Products under Development by Companies, H2 2016 (Contd..42) 242

Products under Development by Companies, H2 2016 (Contd..43) 243

Products under Development by Companies, H2 2016 (Contd..44) 244

Products under Development by Companies, H2 2016 (Contd..45) 245

Products under Development by Companies, H2 2016 (Contd..46) 246

Products under Development by Companies, H2 2016 (Contd..47) 247

Products under Development by Companies, H2 2016 (Contd..48) 248

Products under Development by Companies, H2 2016 (Contd..49) 249

Products under Development by Companies, H2 2016 (Contd..50) 250

Products under Development by Companies, H2 2016 (Contd..51) 251

Products under Development by Companies, H2 2016 (Contd..52) 252

Products under Development by Companies, H2 2016 (Contd..53) 253

Products under Development by Companies, H2 2016 (Contd..54) 254

Products under Development by Companies, H2 2016 (Contd..55) 255

Products under Development by Companies, H2 2016 (Contd..56) 256

Products under Development by Companies, H2 2016 (Contd..57) 257

Products under Development by Companies, H2 2016 (Contd..58) 258

Products under Development by Companies, H2 2016 (Contd..59) 259

Products under Development by Companies, H2 2016 (Contd..60) 260

Products under Development by Companies, H2 2016 (Contd..61) 261

Products under Development by Companies, H2 2016 (Contd..62) 262

Products under Development by Companies, H2 2016 (Contd..63) 263

Products under Development by Companies, H2 2016 (Contd..64) 264

Products under Development by Companies, H2 2016 (Contd..65) 265

Products under Investigation by Universities/Institutes, H2 2016 266

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 267

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 268

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 269

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 270

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 271

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 272

Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 273

Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 274

Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 275

Products under Investigation by Universities/Institutes, H2 2016 (Contd..10) 276

Products under Investigation by Universities/Institutes, H2 2016 (Contd..11) 277

Products under Investigation by Universities/Institutes, H2 2016 (Contd..12) 278

Products under Investigation by Universities/Institutes, H2 2016 (Contd..13) 279

Products under Investigation by Universities/Institutes, H2 2016 (Contd..14) 280

Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016 281

Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 282

Breast Cancer - Pipeline by 3SBio Inc, H2 2016 283

Breast Cancer - Pipeline by 4SC AG, H2 2016 284

Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016 285

Breast Cancer - Pipeline by AB Science SA, H2 2016 286

Breast Cancer - Pipeline by AbbVie Inc, H2 2016 287

Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016 288

Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 289

Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 290

Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 291

Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 292

Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 293

Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016 294

Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 295

Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 296

Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 297

Breast Cancer - Pipeline by Advantagene Inc, H2 2016 298

Breast Cancer - Pipeline by Advaxis Inc, H2 2016 299

Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 300

Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016 301

Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 302

Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016 303

Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 304

Breast Cancer - Pipeline by Affichem SA, H2 2016 305

Breast Cancer - Pipeline by Agenus Inc, H2 2016 306

Breast Cancer - Pipeline by Agilvax Inc, H2 2016 307

Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 308

Breast Cancer - Pipeline by Alchemia Ltd, H2 2016 309

Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 310

Breast Cancer - Pipeline by Alissa Pharma, H2 2016 311

Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016 312

Breast Cancer - Pipeline by Alteogen Inc, H2 2016 313

Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016 314

Breast Cancer - Pipeline by Ambrx Inc, H2 2016 315

Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 316

Breast Cancer - Pipeline by Amgen Inc, H2 2016 317

Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 318

Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016 319

Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016 320

Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016 321

Breast Cancer - Pipeline by AntiCancer Inc, H2 2016 322

Breast Cancer - Pipeline by Antigen Express Inc, H2 2016 323

Breast Cancer - Pipeline by Antoxis Ltd, H2 2016 324

Breast Cancer - Pipeline by Aphios Corp, H2 2016 325

Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016 326

Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 327

Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016 328

Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 329

Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 330

Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 331

Breast Cancer - Pipeline by ArQule Inc, H2 2016 332

Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 333

Breast Cancer - Pipeline by Arvinas Inc, H2 2016 334

Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016 335

Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 336

Breast Cancer - Pipeline by AskAt Inc, H2 2016 337

Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 338

Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016 339

Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 340

Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 341





List of Figures

Number of Products under Development for Breast Cancer, H2 2016 142

Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016 143

Number of Products under Development by Companies, H2 2016 144

Number of Products under Investigation by Universities/Institutes, H2 2016 187

Comparative Analysis by Late Stage Development, H2 2016 196

Comparative Analysis by Clinical Stage Development, H2 2016 197

Comparative Analysis by Early Stage Products, H2 2016 198

Assessment by Monotherapy Products, H2 2016 738

Assessment by Combination Products, H2 2016 739

Number of Products by Top 10 Targets, H2 2016 740

Number of Products by Stage and Top 10 Targets, H2 2016 740

Number of Products by Top 10 Mechanism of Actions, H2 2016 783

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 783

Number of Products by Top 10 Routes of Administration, H2 2016 830

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 830

Number of Products by Top 10 Molecule Types, H2 2016 832

Number of Products by Stage and Top 10 Molecule Types, H2 2016 832

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus